Your browser doesn't support javascript.
loading
A Reduction of Calcineurin Inhibitors May Improve Survival in Patients with De Novo Colorectal Cancer after Liver Transplantation.
Ossami Saidy, Ramin Raul; Wegener, Elisa; Uluk, Deniz; Dittrich, Luca; Schöning, Wenzel; Lurje, Georg; Öllinger, Robert; Modest, Dominik Paul; Tacke, Frank; Haase, Oliver; Pratschke, Johann; Eurich, Dennis.
Afiliación
  • Ossami Saidy RR; Department of Surgery, Campus Charité Mitte | Campus Virchow Klinikum, Charité-Universitätsmedizin Berlin, Charité University Medicine Berlin, 13353 Berlin, Germany.
  • Wegener E; Department of Surgery, Campus Charité Mitte | Campus Virchow Klinikum, Charité-Universitätsmedizin Berlin, Charité University Medicine Berlin, 13353 Berlin, Germany.
  • Uluk D; Department of Surgery, Campus Charité Mitte | Campus Virchow Klinikum, Charité-Universitätsmedizin Berlin, Charité University Medicine Berlin, 13353 Berlin, Germany.
  • Dittrich L; Department of Surgery, Campus Charité Mitte | Campus Virchow Klinikum, Charité-Universitätsmedizin Berlin, Charité University Medicine Berlin, 13353 Berlin, Germany.
  • Schöning W; Department of Surgery, Campus Charité Mitte | Campus Virchow Klinikum, Charité-Universitätsmedizin Berlin, Charité University Medicine Berlin, 13353 Berlin, Germany.
  • Lurje G; Department of Surgery, Campus Charité Mitte | Campus Virchow Klinikum, Charité-Universitätsmedizin Berlin, Charité University Medicine Berlin, 13353 Berlin, Germany.
  • Öllinger R; Department of Surgery, Campus Charité Mitte | Campus Virchow Klinikum, Charité-Universitätsmedizin Berlin, Charité University Medicine Berlin, 13353 Berlin, Germany.
  • Modest DP; Department of Hematology, Oncology and Cancer Immunology, Campus Charité Mitte | Campus Virchow Klinikum, Charité-Universitätsmedizin Berlin, Charité University Medicine Berlin, 13353 Berlin, Germany.
  • Tacke F; Department of Hepatology and Gastroenterology, Campus Charité Mitte | Campus Virchow Klinikum, Charité-Universitätsmedizin Berlin, Charité University Medicine Berlin, 13353 Berlin, Germany.
  • Haase O; Department of Surgery, Campus Charité Mitte | Campus Virchow Klinikum, Charité-Universitätsmedizin Berlin, Charité University Medicine Berlin, 13353 Berlin, Germany.
  • Pratschke J; Department of Surgery, Campus Charité Mitte | Campus Virchow Klinikum, Charité-Universitätsmedizin Berlin, Charité University Medicine Berlin, 13353 Berlin, Germany.
  • Eurich D; Department of Surgery, Campus Charité Mitte | Campus Virchow Klinikum, Charité-Universitätsmedizin Berlin, Charité University Medicine Berlin, 13353 Berlin, Germany.
Medicina (Kaunas) ; 58(12)2022 Nov 29.
Article en En | MEDLINE | ID: mdl-36556957
Background and Objectives: After liver transplantation (LT), long-term immunosuppression (IS) is essential. IS is associated with de novo malignancies, and the incidence of colorectal cancer (CRC) is increased in LT patients. We assessed course of disease in patients with de novo CRC after LT with focus of IS and impact on survival in a retrospective, single-center study. Materials and Methods: All patients diagnosed with CRC after LT between 1988 and 2019 were included. The management of IS regimen following diagnosis and the oncological treatment approach were analyzed: Kaplan−Meier analysis as well as univariate and multivariate analysis were performed. Results: A total of 33 out of 2744 patients were diagnosed with CRC after LT. Two groups were identified: patients with restrictive IS management undergoing dose reduction (RIM group, n = 20) and those with unaltered regimen (maintenance group, n = 13). The groups did not differ in clinical and oncological characteristics. Statistically significant improved survival was found in Kaplan−Meier analysis for patients in the RIM group with 83.46 (8.4−193.1) months in RIM and 24.8 (0.5−298.9) months in the maintenance group (log rank = 0.02) and showed a trend in multivariate cox regression (p = 0.054, HR = 14.3, CI = 0.96−213.67). Conclusions: Immunosuppressive therapy should be reduced further in patients suffering from CRC after LT in an individualized manner to enable optimal oncological therapy and enable improved survival.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / Trasplante de Hígado Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Medicina (Kaunas) Asunto de la revista: MEDICINA Año: 2022 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / Trasplante de Hígado Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Medicina (Kaunas) Asunto de la revista: MEDICINA Año: 2022 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Suiza